Current Hepatic Encephalopathy Therapies Targeting Gut-Liver Axis Disturbance
July 02, 2024
Nancy Reau, MD, leads a discussion on the current abnormality-targeting agents used to prevent and treat hepatic encephalopathy (HE) by addressing the gut-liver axis, specifically focusing on lactulose or lactitol and rifaximin, while also explaining their mechanisms of action and adverse event profiles.